EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Taxation/Internal Revenue Code TAX

HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors.

Contacted: Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); Labor, Dept of (DOL); White House Office; SENATE; Food & Drug Administration (FDA); Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA)

Bills named: H.R. 4 (112th)

Labor Issues/Antitrust/Workplace LBR

Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839). Advocacy surring proposed corporate merger.

Contacted: Defense, Dept of (DOD); SENATE; Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Executive Office of the President (EOP); Federal Trade Commission (FTC); Congressional Budget Office (CBO); Labor, Dept of (DOL); White House Office; HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Bills named: H.R. 1839 (112th), H.R. 1946 (112th), H.R. 1409 (112th)

Health Issues HCR

Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)

Contacted: Congressional Budget Office (CBO); Defense, Dept of (DOD); Food & Drug Administration (FDA); Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Labor, Dept of (DOL); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); SENATE; Government Accountability Office (GAO); Health Resources & Services Administration (HRSA)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (HR 2190, HR 2248, S 1206) & MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733). Policy considerations of the Jt. Comm on Deficit Reduct

Contacted: White House Office; Defense, Dept of (DOD); Government Accountability Office (GAO); Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); SENATE; Congressional Budget Office (CBO); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); Food & Drug Administration (FDA); Labor, Dept of (DOL); Health Resources & Services Administration (HRSA)

Bills named: H.R. 2248 (112th), H.R. 2190 (112th), H.R. 905 (112th), H.R. 891 (112th)

Pharmacy PHA

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058).

Contacted: Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Internal Revenue Service (IRS); Congressional Budget Office (CBO); Labor, Dept of (DOL); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); White House Office; Government Accountability Office (GAO); Executive Office of the President (EOP); SENATE; U.S. Trade Representative (USTR); Defense, Dept of (DOD)

Bills named: H.R. 979 (112th), H.R. 1971 (112th), S. 27 (112th)

Trade (domestic/foreign) TRD

Trans Pacific Partnership trade agreements impact on biosimilar drug market exclusivity length.

Contacted: Federal Trade Commission (FTC); Executive Office of the President (EOP); Government Accountability Office (GAO); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Internal Revenue Service (IRS); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); SENATE; Defense, Dept of (DOD); Food & Drug Administration (FDA); Labor, Dept of (DOL); White House Office; HOUSE OF REPRESENTATIVES

Defense DEF

Pharmacy issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act of 2012.

Contacted: White House Office; Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Health Resources & Services Administration (HRSA); Labor, Dept of (DOL); Executive Office of the President (EOP); Congressional Budget Office (CBO); SENATE; Government Accountability Office (GAO); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)